Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQWL9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $30,808
Award facts
- Contract value 100% obligated
- $30,807.84 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $30.8K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for EXPAREL (liposomal bupivacaine) 266 mg/20 mL vials. This delivery order, issued on January 23, 2026, with an ultimate completion date of February 13, 2026, carries no set-aside designation and uses firm fixed-price pricing. DMS Pharmaceutical Group was selected as the awardee through competitive procurement processes, demonstrating the company's capability to supply specialized pharmaceutical products to Department of Defense medical facilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V), a $30.3 billion government-wide acquisition strategy. The underlying IDC, awarded in November 2025, carries a $500M ceiling and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical regional prime vendor contractor authorized to supply a comprehensive range of pharmaceuticals, biologics, and medical consumables to support Department of Defense healthcare operations globally. The company's established performance across numerous delivery orders demonstrates its reliability as a key supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FQWL9?
SPE2DR26FQWL9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26FQWL9 worth?
The government has obligated $30,808 on SPE2DR26FQWL9.
Is contract SPE2DR26FQWL9 an order under another contract?
Yes. SPE2DR26FQWL9 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWL9 competed?
The extent of competition for SPE2DR26FQWL9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award